Design and rationale of the IN CONTROL trial: the effects of real-time continuous glucose monitoring on glycemia and quality of life in patients with type 1 diabetes mellitus and impaired awareness of hypoglycemia

Cornelis A J van Beers, Susanne J Kleijer, Erik H Serné, Petronella H Geelhoed-Duijvestijn, Frank J Snoek, Mark H H Kramer, Michaela Diamant, Cornelis A J van Beers, Susanne J Kleijer, Erik H Serné, Petronella H Geelhoed-Duijvestijn, Frank J Snoek, Mark H H Kramer, Michaela Diamant

Abstract

Background: Hypoglycemia is the main side effect of intensified insulin therapy in type 1 diabetes and recognized as a limitation in achieving glycemic targets. Patients with impaired awareness of hypoglycemia have a threefold to sixfold increased risk of severe hypoglycemia. Real-time continuous glucose monitoring may help patients with type 1 diabetes to achieve better glycemic control with less hypoglycemic episodes. Accordingly, one may hypothesize that particularly type 1 diabetes mellitus patients with impaired awareness of hypoglycemia will profit most from this technology with improvements in their quality of life. However, this has not yet been established. This trial aims to study the effect of real-time continuous glucose monitoring on glycemia and quality of life specifically in type 1 diabetes mellitus patients with established impaired awareness of hypoglycemia.

Methods/design: This is a two-center, randomized, cross-over trial with a 12-week wash-out period in between intervention periods. A total of 52 type 1 diabetes mellitus patients with impaired awareness of hypoglycemia according to Gold et al. criteria will be randomized to receive real-time continuous glucose monitoring or blinded continuous glucose monitoring for 16 weeks. After a wash-out period, patients will cross over to the other intervention. The primary outcome measure is time spent in euglycemia. Secondary outcomes include (diabetes-specific) markers of quality of life and other glycemic variables.

Discussion: It remains unclear whether patients with type 1 diabetes and impaired awareness of hypoglycemia benefit from real-time continuous glucose monitoring in real-life. This study will provide insight into the potential benefits of real-time continuous glucose monitoring in this patient population.

Trial registration: Clinicaltrials.gov: NCT01787903.

Figures

Fig. 1
Fig. 1
General study plan

References

    1. Forlenza GP, Rewers M. The epidemic of type 1 diabetes: what is it telling us? Curr Opin Endocrinol Diabetes Obes. 2011;18:248–251. doi: 10.1097/MED.0b013e32834872ce.
    1. The Diabetes Control and Complications Trial Research Group The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med. 1993;329:977–986. doi: 10.1056/NEJM199309303291401.
    1. Nathan DM, Cleary PA, Backlund JY, Genuth SM, Lachin JM, Orchard TJ, et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med. 2005;353:2643–2653. doi: 10.1056/NEJMoa052187.
    1. MacLeod KM, Gold AE, Frier BM. Frequency, severity and symptomatology of hypoglycaemia: a comparative trial of human and porcine insulins in type 1 diabetic patients. Diabet Med. 1995;12:134–141. doi: 10.1111/j.1464-5491.1995.tb00444.x.
    1. Pedersen-Bjergaard U, Pramming S, Heller SR, Wallace TM, Rasmussen AK, Jorgensen HV, et al. Severe hypoglycaemia in 1076 adult patients with type 1 diabetes: influence of risk markers and selection. Diabetes Metab Res Rev. 2004;20:479–486. doi: 10.1002/dmrr.482.
    1. Pramming S, Thorsteinsson B, Bendtson I, Binder C. Symptomatic hypoglycaemia in 411 type 1 diabetic patients. Diabet Med. 1991;8:217–222. doi: 10.1111/j.1464-5491.1991.tb01575.x.
    1. Donnelly LA, Morris AD, Frier BM, Ellis JD, Donnan PT, Durrant R, et al. Frequency and predictors of hypoglycaemia in Type 1 and insulin-treated Type 2 diabetes: a population-based study. Diabet Med. 2005;22:749–755. doi: 10.1111/j.1464-5491.2005.01501.x.
    1. MacLeod KM, Hepburn DA, Frier BM. Frequency and morbidity of severe hypoglycaemia in insulin-treated diabetic patients. Diabet Med. 1993;10:238–245. doi: 10.1111/j.1464-5491.1993.tb00051.x.
    1. ter Braak EW, Appelman AM, van de Laak M, Stolk RP, van Haeften TW, Erkelens DW. Clinical characteristics of type 1 diabetic patients with and without severe hypoglycemia. Diabetes Care. 2000;23:1467–1471. doi: 10.2337/diacare.23.10.1467.
    1. Cryer PE. Hypoglycaemia: the limiting factor in the glycaemic management of Type I and Type II diabetes. Diabetologia. 2002;45:937–948. doi: 10.1007/s00125-002-0822-9.
    1. Cryer PE, Davis SN, Shamoon H. Hypoglycemia in diabetes. Diabetes Care. 2003;26:1902–1912. doi: 10.2337/diacare.26.6.1902.
    1. Workgroup on Hypoglycemia ADA Defining and reporting hypoglycemia in diabetes: a report from the American Diabetes Association Workgroup on Hypoglycemia. Diabetes Care. 2005;28:1245–1249. doi: 10.2337/diacare.28.5.1245.
    1. Frier BM. How hypoglycaemia can affect the life of a person with diabetes. Diabetes Metab Res Rev. 2008;24:87–92. doi: 10.1002/dmrr.796.
    1. Frier BM. Hypoglycaemia in diabetes mellitus: epidemiology and clinical implications. Nat Rev Endocrinol. 2014;10(12):711–722. doi: 10.1038/nrendo.2014.170.
    1. Hepburn DA, Patrick AW, Brash HM, Thomson I, Frier BM. Hypoglycaemia unawareness in type 1 diabetes: a lower plasma glucose is required to stimulate sympatho-adrenal activation. Diabet Med. 1991;8:934–945. doi: 10.1111/j.1464-5491.1991.tb01533.x.
    1. Gold AE, MacLeod KM, Frier BM. Frequency of severe hypoglycemia in patients with type I diabetes with impaired awareness of hypoglycemia. Diabetes Care. 1994;17:697–703. doi: 10.2337/diacare.17.7.697.
    1. Clarke WL, Cox DJ, Gonder-Frederick LA, Julian D, Schlundt D, Polonsky W. Reduced awareness of hypoglycemia in adults with IDDM. A prospective study of hypoglycemic frequency and associated symptoms. Diabetes Care. 1995;18:517–522. doi: 10.2337/diacare.18.4.517.
    1. Geddes J, Wright RJ, Zammitt NN, Deary IJ, Frier BM. An evaluation of methods of assessing impaired awareness of hypoglycemia in type 1 diabetes. Diabetes Care. 2007;30:1868–1870. doi: 10.2337/dc06-2556.
    1. Geddes J, Schopman JE, Zammitt NN, Frier BM. Prevalence of impaired awareness of hypoglycaemia in adults with Type 1 diabetes. Diabet Med. 2008;25:501–504. doi: 10.1111/j.1464-5491.2008.02413.x.
    1. Feltbower RG, Bodansky HJ, Patterson CC, Parslow RC, Stephenson CR, Reynolds C, et al. Acute complications and drug misuse are important causes of death for children and young adults with type 1 diabetes: results from the Yorkshire Register of diabetes in children and young adults. Diabetes Care. 2008;31:922–926. doi: 10.2337/dc07-2029.
    1. Patterson CC, Dahlquist G, Harjutsalo V, Joner G, Feltbower RG, Svensson J, et al. Early mortality in EURODIAB population-based cohorts of type 1 diabetes diagnosed in childhood since 1989. Diabetologia. 2007;50:2439–2442. doi: 10.1007/s00125-007-0824-8.
    1. Lind M, Svensson AM, Kosiborod M, Gudbjornsdottir S, Pivodic A, Wedel H, et al. Glycemic control and excess mortality in type 1 diabetes. N Engl J Med. 2014;371:1972–1982. doi: 10.1056/NEJMoa1408214.
    1. Garg S, Zisser H, Schwartz S, Bailey T, Kaplan R, Ellis S, et al. Improvement in glycemic excursions with a transcutaneous, real-time continuous glucose sensor: a randomized controlled trial. Diabetes Care. 2006;29:44–50. doi: 10.2337/diacare.29.01.06.dc05-1686.
    1. Feldman B, Brazg R, Schwartz S, Weinstein R. A continuous glucose sensor based on wired enzyme technology -- results from a 3-day trial in patients with type 1 diabetes. Diabetes Technol Ther. 2003;5:769–779. doi: 10.1089/152091503322526978.
    1. Keenan DB, Mastrototaro JJ, Voskanyan G, Steil GM. Delays in minimally invasive continuous glucose monitoring devices: a review of current technology. J Diabetes Sci Technol. 2009;3:1207–1214. doi: 10.1177/193229680900300528.
    1. Weinstein RL, Schwartz SL, Brazg RL, Bugler JR, Peyser TA, McGarraugh GV. Accuracy of the 5-day FreeStyle Navigator Continuous Glucose Monitoring System: comparison with frequent laboratory reference measurements. Diabetes Care. 2007;30:1125–1130. doi: 10.2337/dc06-1602.
    1. Bode B, Gross K, Rikalo N, Schwartz S, Wahl T, Page C, et al. Alarms based on real-time sensor glucose values alert patients to hypo- and hyperglycemia: the guardian continuous monitoring system. Diabetes Technol Ther. 2004;6:105–113. doi: 10.1089/152091504773731285.
    1. Geelhoed-Duijvestijn PH, Box F, Diamant M, Otoide-Vree M, Niel Van J. Real time continuous glucose monitoring: how does it work in real life? Br J Diab Vasc Dis. 2011;11:145–149. doi: 10.1177/1474651411413500.
    1. Bergenstal RM, Tamborlane WV, Ahmann A, Buse JB, Dailey G, Davis SN, et al. Effectiveness of sensor-augmented insulin-pump therapy in type 1 diabetes. N Engl J Med. 2010;363:311–320. doi: 10.1056/NEJMoa1002853.
    1. Bergenstal RM, Tamborlane WV, Ahmann A, Buse JB, Dailey G, Davis SN, et al. Sensor-augmented pump therapy for A1C reduction (STAR 3) study: results from the 6-month continuation phase. Diabetes Care. 2011;34:2403–2405. doi: 10.2337/dc11-1248.
    1. Bode B, Beck RW, Xing D, Gilliam L, Hirsch I, Kollman C, et al. Sustained benefit of continuous glucose monitoring on A1C, glucose profiles, and hypoglycemia in adults with type 1 diabetes. Diabetes Care. 2009;32:2047–2049. doi: 10.2337/dc09-0846.
    1. Danne T, De Valk HW, Kracht T, Walte K, Geldmacher R, Solter L, et al. Reducing glycaemic variability in type 1 diabetes self-management with a continuous glucose monitoring system based on wired enzyme technology. Diabetologia. 2009;52:1496–1503. doi: 10.1007/s00125-009-1408-6.
    1. Deiss D, Bolinder J, Riveline JP, Battelino T, Bosi E, Tubiana-Rufi N, et al. Improved glycemic control in poorly controlled patients with type 1 diabetes using real-time continuous glucose monitoring. Diabetes Care. 2006;29:2730–2732. doi: 10.2337/dc06-1134.
    1. Garg SK, Schwartz S, Edelman SV. Improved glucose excursions using an implantable real-time continuous glucose sensor in adults with type 1 diabetes. Diabetes Care. 2004;27:734–738. doi: 10.2337/diacare.27.3.734.
    1. Hirsch IB, Abelseth J, Bode BW, Fischer JS, Kaufman FR, Mastrototaro J, et al. Sensor-augmented insulin pump therapy: results of the first randomized treat-to-target study. Diabetes Technol Ther. 2008;10:377–383. doi: 10.1089/dia.2008.0068.
    1. Ludvigsson J, Hanas R. Continuous subcutaneous glucose monitoring improved metabolic control in pediatric patients with type 1 diabetes: a controlled crossover study. Pediatrics. 2003;111:933–938. doi: 10.1542/peds.111.5.933.
    1. Raccah D, Sulmont V, Reznik Y, Guerci B, Renard E, Hanaire H, et al. Incremental value of continuous glucose monitoring when starting pump therapy in patients with poorly controlled type 1 diabetes: the RealTrend study. Diabetes Care. 2009;32:2245–2250. doi: 10.2337/dc09-0750.
    1. Radermecker RP, Saint RA, Scheen AJ, Bringer J, Renard E. Continuous glucose monitoring reduces both hypoglycaemia and HbA1c in hypoglycaemia-prone type 1 diabetic patients treated with a portable pump. Diabetes Metab. 2010;36:409–413. doi: 10.1016/j.diabet.2010.08.001.
    1. Rodbard D, Bailey T, Jovanovic L, Zisser H, Kaplan R, Garg SK. Improved quality of glycemic control and reduced glycemic variability with use of continuous glucose monitoring. Diabetes Technol Ther. 2009;11:717–723. doi: 10.1089/dia.2009.0077.
    1. Tamborlane WV, Beck RW, Bode BW, Buckingham B, Chase HP, Clemons R, et al. Continuous glucose monitoring and intensive treatment of type 1 diabetes. N Engl J Med. 2008;359:1464–1476. doi: 10.1056/NEJMoa0805017.
    1. Hermanides J, Norgaard K, Bruttomesso D, Mathieu C, Frid A, Dayan CM, et al. Sensor-augmented pump therapy lowers HbA(1c) in suboptimally controlled Type 1 diabetes; a randomized controlled trial. Diabet Med. 2011;28:1158–1167. doi: 10.1111/j.1464-5491.2011.03256.x.
    1. Davey RJ, Jones TW, Fournier PA. Effect of short-term use of a continuous glucose monitoring system with a real-time glucose display and a low glucose alarm on incidence and duration of hypoglycemia in a home setting in type 1 diabetes mellitus. J Diabetes Sci Technol. 2010;4:1457–1464. doi: 10.1177/193229681000400620.
    1. Beck RW, Hirsch IB, Laffel L, Tamborlane WV, Bode BW, Buckingham B, et al. The effect of continuous glucose monitoring in well-controlled type 1 diabetes. Diabetes Care. 2009;32:1378–1383. doi: 10.2337/dc09-0108.
    1. Battelino T, Phillip M, Bratina N, Nimri R, Oskarsson P, Bolinder J. Effect of continuous glucose monitoring on hypoglycemia in type 1 diabetes. Diabetes Care. 2011;34:795–800. doi: 10.2337/dc10-1989.
    1. Little SA, Leelarathna L, Walkinshaw E, Tan HK, Chapple O, Lubina-Solomon A, et al. Recovery of Hypoglycemia Awareness in Long-standing Type 1 Diabetes: A Multicenter 2 x 2 Factorial Randomized Controlled Trial Comparing Insulin Pump With Multiple Daily Injections and Continuous With Conventional Glucose Self-monitoring (HypoCOMPaSS) Diabetes Care. 2014;37:2114–2122. doi: 10.2337/dc14-0030.
    1. Deiss D, Hartmann R, Schmidt J, Kordonouri O. Results of a randomised controlled cross-over trial on the effect of continuous subcutaneous glucose monitoring (CGMS) on glycaemic control in children and adolescents with type 1 diabetes. Exp Clin Endocrinol Diabetes. 2006;114:63–67. doi: 10.1055/s-2006-923887.
    1. Tansey M, Laffel L, Cheng J, Beck R, Coffey J, Huang E, et al. Satisfaction with continuous glucose monitoring in adults and youths with Type 1 diabetes. Diabet Med. 2011;28:1118–1122. doi: 10.1111/j.1464-5491.2011.03368.x.
    1. Davey RJ, Stevens K, Jones TW, Fournier PA. The effect of short-term use of the Guardian RT continuous glucose monitoring system on fear of hypoglycaemia in patients with type 1 diabetes mellitus. Prim Care Diabetes. 2011;6(1):35–39. doi: 10.1016/j.pcd.2011.09.004.
    1. American Diabetes Association Diagnosis and classification of diabetes mellitus. Diabetes Care. 2012;35(1):S64–S71. doi: 10.2337/dc12-s064.
    1. Langan SJ, Deary IJ, Hepburn DA, Frier BM. Cumulative cognitive impairment following recurrent severe hypoglycaemia in adult patients with insulin-treated diabetes mellitus. Diabetologia. 1991;34:337–344. doi: 10.1007/BF00405006.
    1. Nathan DM, Rosenbaum C, Protasowicki VD. Single-void urine samples can be used to estimate quantitative microalbuminuria. Diabetes Care. 1987;10:414–418. doi: 10.2337/diacare.10.4.414.
    1. Mogensen CE, Keane WF, Bennett PH, Jerums G, Parving HH, Passa P, et al. Prevention of diabetic renal disease with special reference to microalbuminuria. Lancet. 1995;346:1080–1084. doi: 10.1016/S0140-6736(95)91747-0.
    1. Bril V, Tomioka S, Buchanan RA, Perkins BA. Reliability and validity of the modified Toronto Clinical Neuropathy Score in diabetic sensorimotor polyneuropathy. Diabet Med. 2009;26:240–246. doi: 10.1111/j.1464-5491.2009.02667.x.
    1. Martin CL, Waberski BH, Pop-Busui R, Cleary PA, Catton S, Albers JW, et al. Vibration perception threshold as a measure of distal symmetrical peripheral neuropathy in type 1 diabetes: results from the DCCT/EDIC study. Diabetes Care. 2010;33:2635–2641. doi: 10.2337/dc10-0616.
    1. Aldington SJ, Kohner EM, Meuer S, Klein R, Sjolie AK. Methodology for retinal photography and assessment of diabetic retinopathy: the EURODIAB IDDM complications study. Diabetologia. 1995;38:437–444. doi: 10.1007/BF00410281.
    1. Guidelines ADA. Standards of medical care in diabetes--2012. Diabetes Care. 2012;2012(35 Suppl 1):S11–S63.
    1. McGuire BE, Morrison TG, Hermanns N, Skovlund S, Eldrup E, Gagliardino J, et al. Short-form measures of diabetes-related emotional distress: the Problem Areas in Diabetes Scale (PAID)-5 and PAID-1. Diabetologia. 2010;53:66–69. doi: 10.1007/s00125-009-1559-5.
    1. Cox DJ, Irvine A, Gonder-Frederick L, Nowacek G, Butterfield J. Fear of hypoglycemia: quantification, validation, and utilization. Diabetes Care. 1987;10:617–621. doi: 10.2337/diacare.10.5.617.
    1. Gonder-Frederick LA, Schmidt KM, Vajda KA, Greear ML, Singh H, Shepard JA, et al. Psychometric properties of the hypoglycemia fear survey-ii for adults with type 1 diabetes. Diabetes Care. 2011;34:801–806. doi: 10.2337/dc10-1343.
    1. Van Der Ven NC, Weinger K, Yi J, Pouwer F, Ader H, Van Der Ploeg HM, et al. The confidence in diabetes self-care scale: psychometric properties of a new measure of diabetes-specific self-efficacy in Dutch and US patients with type 1 diabetes. Diabetes Care. 2003;26:713–718. doi: 10.2337/diacare.26.3.713.
    1. Linde L, Sorensen J, Ostergaard M, Horslev-Petersen K, Hetland ML. Health-related quality of life: validity, reliability, and responsiveness of SF-36, 15D, EQ-5D [corrected] RAQoL, and HAQ in patients with rheumatoid arthritis. J Rheumatol. 2008;35:1528–1537.
    1. Savoia E, Fantini MP, Pandolfi PP, Dallolio L, Collina N. Assessing the construct validity of the Italian version of the EQ-5D: preliminary results from a cross-sectional study in North Italy. Health Qual Life Outcomes. 2006;4:47. doi: 10.1186/1477-7525-4-47.
    1. Awata S, Bech P, Yoshida S, Hirai M, Suzuki S, Yamashita M, et al. Reliability and validity of the Japanese version of the World Health Organization-Five Well-Being Index in the context of detecting depression in diabetic patients. Psychiatry Clin Neurosci. 2007;61:112–119. doi: 10.1111/j.1440-1819.2007.01619.x.
    1. De Wit M, Pouwer F, Gemke RJ, Delemarre-van De Waal HA, Snoek FJ. Validation of the WHO-5 Well-Being Index in adolescents with type 1 diabetes. Diabetes Care. 2007;30:2003–2006. doi: 10.2337/dc07-0447.
    1. Lowe B, Spitzer RL, Grafe K, Kroenke K, Quenter A, Zipfel S, et al. Comparative validity of three screening questionnaires for DSM-IV depressive disorders and physicians’ diagnoses. J Affect Disord. 2004;78:131–140. doi: 10.1016/S0165-0327(02)00237-9.
    1. McDonnell CM, Donath SM, Vidmar SI, Werther GA, Cameron FJ. A novel approach to continuous glucose analysis utilizing glycemic variation. Diabetes Technol Ther. 2005;7:253–263. doi: 10.1089/dia.2005.7.253.
    1. Molnar GD, Taylor WF, Ho MM. Day-to-day variation of continuously monitored glycaemia: a further measure of diabetic instability. Diabetologia. 1972;8:342–348. doi: 10.1007/BF01218495.
    1. Jarrin DC, McGrath JJ, Giovanniello S, Poirier P, Lambert M. Measurement fidelity of heart rate variability signal processing: The devil is in the details. Int J Psychophysiol. 2012;86(1):88–97. doi: 10.1016/j.ijpsycho.2012.07.004.
    1. Spallone V, Ziegler D, Freeman R, Bernardi L, Frontoni S, Pop-Busui R, et al. Cardiovascular autonomic neuropathy in diabetes: clinical impact, assessment, diagnosis, and management. Diabetes Metab Res Rev. 2011;27(7):639–653. doi: 10.1002/dmrr.1239.
    1. Ewing DJ, Martyn CN, Young RJ, Clarke BF. The value of cardiovascular autonomic function tests: 10 years experience in diabetes. Diabetes Care. 1985;8:491–498. doi: 10.2337/diacare.8.5.491.
    1. Spallone V, Bellavere F, Scionti L, Maule S, Quadri R, Bax G, et al. Recommendations for the use of cardiovascular tests in diagnosing diabetic autonomic neuropathy. Nutr Metab Cardiovasc Dis. 2011;21:69–78. doi: 10.1016/j.numecd.2010.07.005.
    1. Consensus statement: Report and recommendations of the San Antonio conference on diabetic neuropathy. American Diabetes Association American Academy of Neurology. Diabetes Care 1988, 11: 592–597.
    1. Diabetes Research in Children Network (DirecNet) Study Group Youth and parent satisfaction with clinical use of the GlucoWatch G2 Biographer in the management of pediatric type 1 diabetes. Diabetes Care. 2005;28:1929–1935. doi: 10.2337/diacare.28.8.1929.
    1. Kropff J, Bruttomesso D, Doll W, Farret A, Galasso S, Luijf YM, et al. Accuracy of two continuous glucose monitoring systems: a head-to-head comparison under clinical research centre and daily life conditions. Diabetes Obes Metab. 2015;17:343–349. doi: 10.1111/dom.12378.
    1. Keenan DB, Cartaya R, Mastrototaro JJ. Accuracy of a new real-time continuous glucose monitoring algorithm. J Diabetes Sci Technol. 2010;4:111–118. doi: 10.1177/193229681000400114.
    1. Clarke WL, Anderson S, Farhy L, Breton M, Gonder-Frederick L, Cox D, et al. Evaluating the clinical accuracy of two continuous glucose sensors using continuous glucose-error grid analysis. Diabetes Care. 2005;28:2412–2417. doi: 10.2337/diacare.28.10.2412.
    1. Kovatchev B, Anderson S, Heinemann L, Clarke W. Comparison of the numerical and clinical accuracy of four continuous glucose monitors. Diabetes Care. 2008;31:1160–1164. doi: 10.2337/dc07-2401.
    1. Brown BW., Jr The crossover experiment for clinical trials. Biometrics. 1980;36:69–79. doi: 10.2307/2530496.
    1. Koch GG. The use of non-parametric methods in the statistical analysis of the two-period change-over design. Biometrics. 1972;28:577–584. doi: 10.2307/2556170.
    1. McGowan K, Thomas W, Moran A. Spurious reporting of nocturnal hypoglycemia by CGMS in patients with tightly controlled type 1 diabetes. Diabetes Care. 2002;25:1499–1503. doi: 10.2337/diacare.25.9.1499.
    1. Ly TT, Hewitt J, Davey RJ, Lim EM, Davis EA, Jones TW. Improving epinephrine responses in hypoglycemia unawareness with real-time continuous glucose monitoring in adolescents with type 1 diabetes. Diabetes Care. 2011;34:50–52. doi: 10.2337/dc10-1042.
    1. Choudhary P, Ramasamy S, Green L, Gallen G, Pender S, Brackenridge A, et al. Real-time continuous glucose monitoring significantly reduces severe hypoglycemia in hypoglycemia-unaware patients with type 1 diabetes. Diabetes Care. 2013;36:4160–4162. doi: 10.2337/dc13-0939.
    1. Ly TT, Nicholas JA, Retterath A, Lim EM, Davis EA, Jones TW. Effect of sensor-augmented insulin pump therapy and automated insulin suspension vs standard insulin pump therapy on hypoglycemia in patients with type 1 diabetes: a randomized clinical trial. JAMA. 2013;310:1240–1247. doi: 10.1001/jama.2013.277818.
    1. Pedersen-Bjergaard U, Pramming S, Thorsteinsson B. Recall of severe hypoglycaemia and self-estimated state of awareness in type 1 diabetes. Diabetes Metab Res Rev. 2003;19:232–240. doi: 10.1002/dmrr.377.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe